Freenome
Early cancer detection company developing multiomics blood-based screening tests using machine learning.
Source: Digital.Health
Digital.Health provided this information. To learn more and get deep data on digital health companies, please visit them here.
Visit Digital.Health →Why it matters
Freenome sits at the intersection of preventive screening, AI diagnostics, and blood-based cancer detection, a market with strong payer, employer, and public health implications.
Products
Freenome early cancer screening platform
Multiomics blood-based screening platform combining tumor and non-tumor signals with machine learning.
Learn more →What the company reports
Claims are attributed to their source and not independently verified unless noted.
Freenome's platform uses multiomics technology to detect cancer in its earliest, most treatable stages.
Company statessource →Freenome's multiomics approach combines tumor and non-tumor signals from DNA and protein with machine learning.
Company statessource →Freenome announced expanded AI/deep-learning initiatives with NVIDIA in January 2026.
Company statessource →
Core Technology
Multiomics, Machine Learning, Blood-Based Screening, Computational Biology
Company Info
- Business Model
- Diagnostics, Clinical Testing, Research Partnerships
- Website
- www.freenome.com/
MedStartr Index Score
?What do you think of Freenome?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.